<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="src/test/resources/org/contentmine/ami/zika10/PMC3113902/results/search/disease/results.xml">
  <result pre="expression coincides with lack of detectable levels of CIITA. In" exact="cancer" post="the transcriptional silencing of MHC2TA and resulting extinction of"/>
  <result pre="modifications of histones. The lack of CIITA expression in several" exact="cancer" post="types is associated with CpG dinucleotide methylation of CIITA-PIV"/>
  <result pre="Kanaseki et al., 2003; Chou et al., 2005). In a" exact="uveal melanoma" post="tumor cell line it was demonstrated for the first"/>
  <result pre="in the transcriptional downregulation of IFNγ-induced expression of CIITA in" exact="uveal melanoma" post="(Holling et al., 2007). Notably, the transcriptional silencing of"/>
  <result pre="the 3meK27-H3 modification pre-marks genes for de novo methylation in" exact="cancer" post="(Schlesinger et al., 2007). It could therefore be argued"/>
  <result pre="argued that the epigenetic make-up of the CIITA-PIV region in" exact="uveal melanoma" post="reflects pre-marking for de novo methylation of DNA, and"/>
  <result pre="histone acetylation and methylation marks in CIITA-PIII chromatin in T" exact="leukemia" post="cell lines lacking MHC-II molecule expression (Van Eggermond et"/>
  <result pre="al., 2011). In contrast, CIITA and MHC-II molecule expressing T" exact="lymphoma" post="cells displayed the opposite phenotype. As detailed above, in"/>
  <result pre="cells displayed the opposite phenotype. As detailed above, in T" exact="leukemia" post="cells these repressive histone marks were also found to"/>
  <result pre="MHC2TA multi-promoter region, while the opposite was noted for T" exact="lymphoma" post="cells (Van Eggermond et al., 2011). The high levels"/>
  <result pre="levels of KMT6 at the various CIITA promoters in T" exact="leukemia" post="cells, while CIITA expressing T lymphoma cells displayed a"/>
  <result pre="CIITA promoters in T leukemia cells, while CIITA expressing T" exact="lymphoma" post="cells displayed a general lack of KMT6 (Van Eggermond"/>
  <result pre="epigenetic mechanisms as observed under pathological conditions such as in" exact="cancer" post="and autoimmune disease might provide an opportunity for pharmacological"/>
  <result pre="as observed under pathological conditions such as in cancer and" exact="autoimmune disease" post="might provide an opportunity for pharmacological interference targeting the"/>
  <result pre="I binding factor 1 silences class II transactivator expression in" exact="multiple myeloma" post="cells . J. Biol. Chem. 276, 15264– 15268 10.1074/jbc.M008831200"/>
  <result pre="for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in" exact="uveal melanoma" post=". J. Immunol. 179, 5317– 5325 17911618 Holling T."/>
  <result pre="alleviate silencing of class II transactivator gene expression in L1210" exact="lymphoma" post="cells . J. Immunol. 169, 3085– 3093 12218125 Murphy"/>
  <result pre="the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric" exact="cancer" post="cells . Oncogene 23, 8876– 8886 10.1038/sj.onc.1208144 15467734 Schlesinger"/>
  <result pre="of histone H3 pre-marks genes for de novo methylation in" exact="cancer" post=". Nat. Genet. 39, 232– 236 10.1038/ng1950 17200670 Silacci"/>
  <result pre="transactivator causes severe deficiency of HLA-DR expression in small cell" exact="lung cancer" post=". J. Pathol. 187, 191– 199 10.1002/(SICI)1096-9896(199901)187:2&amp;lt;191::AID-PATH206&amp;gt;3.0.CO;2-3 10365094 Yu"/>
  <result pre="causes severe deficiency of HLA-DR expression in small cell lung" exact="cancer" post=". J. Pathol. 187, 191– 199 10.1002/(SICI)1096-9896(199901)187:2&amp;lt;191::AID-PATH206&amp;gt;3.0.CO;2-3 10365094 Yu"/>
 </snippets>
</snippetsTree>
